Paul Hudson promises a bright new future at Sanofi, kicking loose me-too drugs and focusing on landmark advances. But can he deliver?
Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.
Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class. The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.